

# Rapid Sequencing of the *Mycobacterium tuberculosis pncA* Gene for Detection of Pyrazinamide Susceptibility

Elizabeth M. Streicher,<sup>a</sup> Kashmeel Maharaj,<sup>b</sup> Talita York,<sup>a</sup> Carel Van Heerden,<sup>c</sup> Marinus Barnard,<sup>a,d</sup> Andreas Diacon,<sup>a,d</sup> Carl M. Mendel,<sup>e</sup> Marlein E. Bosman,<sup>f</sup> Juli A. Hepple,<sup>a</sup> Alexander S. Pym,<sup>b</sup> Robin M. Warren,<sup>a</sup> Paul D. van Helden<sup>a</sup>

DST/NRF Centre of Excellence for Biomedical Tuberculosis Research/MRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa<sup>a</sup>; KwaZulu-Natal Research Institute for Tuberculosis and HIV, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa<sup>b</sup>; Central Analytical Facilities, Stellenbosch University, Stellenbosch, South Africa<sup>c</sup>; Division of Medical Physiology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa<sup>d</sup>; TB Alliance, New York, New York, USA<sup>e</sup>; National Health Laboratory Service, Cape Town, South Africa<sup>f</sup>

**We developed a pyrazinamidase gene DNA-sequencing method to rapidly identify pyrazinamide resistance-causing mutations in GenoLyse-treated, smear-positive sputum specimens. The sensitivity and specificity were 90.9 and 100%, respectively, compared to those of MGIT drug susceptibility testing, after the exclusion of synonymous mutations and nonsynonymous mutations previously associated with susceptibility to pyrazinamide.**

Tuberculosis (TB) clinical trials are planned for the evaluation of new treatment regimens that include pyrazinamide (PZA); however, culture-based methods for the detection of PZA resistance are complicated because: pyrazinamidase (PZase) is active at low pH only, results are influenced by inoculum size, and the assays are difficult and time-consuming (1, 2). Alternative methods to rapidly screen for PZA susceptibility need to be evaluated. Point mutations in the *pncA* gene, which encodes PZase, are the primary mechanism of resistance to PZA (3, 4); however, mutations and/or polymorphisms occur across the entire length of the gene, and thus, sequencing of the entire *pncA* gene is necessary to capture all of the possible mutations (5). Here we evaluated *pncA* DNA sequencing to detect PZA resistance-conferring mutations directly in clinical specimens.

To determine the diagnostic performance characteristics of *pncA* gene sequencing, a set of 85 of 167 stored, GenoLyse-treated specimens from the NC-002 clinical trial (TB Alliance) were selected because these specimens also had MGIT PZA drug susceptibility data (Becton, Dickinson and Company, NJ, USA). All 85 GenoLyse-treated specimens had been stored on their pellets, contrary to the manufacturer's instructions (Hain Lifescience, Germany). Ethical approval was obtained from the Health Research Ethics Committee of Stellenbosch University, Pharma Ethics, University of Witwatersrand and University of Cape Town.

The *pncA* gene was amplified with primers JpncAs Forward (5' GGCGTCATGGACCCTATA 3') and JpncAs Reverse (5' GTGA ACAACCCGACCCAG 3'). These primers were designed to amplify a product of 738 bp that includes the full length of the *pncA* gene (561 bp), as well as 80 bp of the upstream sequence and 97 bp of the downstream sequence. Each reaction mixture (25  $\mu$ l) contained 1 to 2.5  $\mu$ l of template DNA (GenoLyse-treated sputum specimen), 0.75  $\mu$ M each PCR primer (IDT), 1 $\times$  buffer, 0.8 mM deoxynucleoside triphosphates, 0.125  $\mu$ l (0.625 U) of HotStarTaq polymerase (Qiagen, Germany), and 2  $\mu$ M Syto9 green-fluorescent nucleic acid stain (Invitrogen, CA, USA). The amplification protocol consisted of an initial activation step of 95°C for 15 min, followed by 50 cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 1 min and a final elongation step of 10 min at 72°C. Water was included as a negative control, while H37Rv DNA was included as a positive control. Amplification was confirmed by the detection

of a distinct fluorescent melting curve signature consisting of two maxima ( $\pm$ 92°C and  $\pm$ 93.5°C, respectively) by high-resolution melting analysis. Post-PCR cleanup was done with the Agencourt AMPure XP PCR1 purification system (Agencourt Bioscience Corporation, Beckman Coulter, Beverly, MA). PCR products were sequenced in both directions with the JpncAs Forward and JpncAs Reverse primers. The DNA sequencing reaction was done on a GeneAmp 9700 thermal cycler (Applied Biosystems, Foster City, CA, USA) with the following program: 5 min at 94°C, followed by 25 cycles of 94°C for 10 s, 55°C for 10 s, and 60°C for 4 min, using the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Austin, TX, USA). The products were then electrophoresed on an ABI3730xl genetic analyzer (Applied Biosystems, Foster City, CA, USA). Sequences were analyzed on the BioEdit sequence alignment editor (<http://www.mbio.ncsu.edu/bioedit/bioedit.html>) with H37Rv as the reference strain. The sensitivity and specificity of the DNA sequencing method were determined with Statistica 7.1.

Table 1 shows that 78 (91.8%) specimens were amplifiable and gave interpretable DNA sequences. The absence of amplification in the remaining seven (8.2%) specimens was ascribed to the storage of the GenoLyse extracts on their pellets. *pncA* sequences were available for 11 of 13 samples with a resistance phenotype (1 had a wild-type sequence, and 10 had nonsynonymous mutations) (see Table S1 in the supplemental material). *pncA* sequences were available for 67 of the 72 PZA-susceptible samples (2 had synonymous mutations, 4 had nonsynonymous mutations, and 61 had wild-type sequences [see Table S1 in the supplemental material]). Review of the four nonsynonymous mutations showed that they

Received 22 August 2014 Accepted 22 August 2014

Published ahead of print 27 August 2014

Editor: R. Patel

Address correspondence to Robin M. Warren, [rw1@sun.ac.za](mailto:rw1@sun.ac.za).

Supplemental material for this article may be found at <http://dx.doi.org/10.1128/JCM.02438-14>.

Copyright © 2014, American Society for Microbiology. All Rights Reserved.

doi:10.1128/JCM.02438-14

**TABLE 1** Comparison of *pncA* sequencing results and Bactec MGIT 960 PZA drug susceptibility test results

| Bactec MGIT PZA drug susceptibility test or <i>pncA</i> sequencing result | No. (%) of samples   |
|---|----------------------|
| PZA resistant ( <i>n</i> = 13)  |                      |
| <i>pncA</i> nonsynonymous mutation  | 10 (76.9)            |
| <i>pncA</i> wild type   | 1 (7.7)              |
| PCR negative  | 2 (15.4)             |
| PZA susceptible ( <i>n</i> = 72)  |                      |
| <i>pncA</i> wild type   | 61 (84.7)            |
| <i>pncA</i> synonymous mutation   | 2 (2.8)              |
| <i>pncA</i> nonsynonymous mutation  | 4 <sup>a</sup> (5.6) |
| PCR negative  | 5 (6.9)              |

<sup>a</sup> All previously associated with low-level PZA phenotypic resistance (6–10).

had been previously associated with PZA susceptibility or low-level resistance (V130A, L35R, and T114M) (6–10). Thus, a total of 77 (98.7%) of the 78 specimens would have been correctly scored on the basis of an algorithm that incorporates previously described genotype-phenotype relationships. This translates to a sensitivity and specificity of 90.9% (95% confidence interval [CI] = 0.739 to 1.079) and 100% (95% CI = 1.0), respectively, assuming that the MGIT susceptibility results were correct. The negative and positive predictive values were 0.985 and 1.000, respectively.

Our turnaround time for PCR and DNA sequencing was 43 h, compared to conventional culture's 26 days (range, 12 to 195 days). This shortened time to diagnosis will ensure that patients with a high risk of PZA resistance (multidrug-resistant TB [MDR-TB]) are not exposed to inappropriate therapy for an extended period and can be excluded from trials where PZA is central to therapy.

The diagnostic value of the DNA-sequencing method relies on our knowledge of the relationship between the genotype and the phenotype. Review of the current literature shows that 87 to 95% of the isolates determined phenotypically to be PZA resistant harbor nonsynonymous mutations in the *pncA* gene (5). PZA resistance in the remaining 5 to 13% of the isolates may occur through mutations in other genes, including the *rpsA* gene (11, 12) or could be false positives of the phenotypic assays (2, 13). Inclusion of the *rpsA* gene may improve the assay. Mutations in *pncA* are not restricted to PZA-resistant isolates, and synonymous and nonsynonymous mutations have been documented in PZA-susceptible isolates. Pending a full, definitive, quantitative understanding of the relationship between *pncA* mutation and PZA susceptibility, we propose that wild-type sequences should be considered susceptible with a low risk of PZA resistance through alternative mechanisms. Mutations in *pncA* should be considered resistant unless synonymous or previously proven to not confer resistance.

Two additional limitations were noted. First, correct storage of GenoLyse DNA extracts is essential for consistent PCR amplification. This can be overcome by aspiration of the extracted DNA into a clean tube, followed by storage at  $-80^{\circ}\text{C}$ , as recommended by the manufacturer. Second, the DNA sequencing method was tested on DNA extracts from smear-positive sputum samples

only, and it is therefore not plausible at this time to extrapolate these findings to smear-negative sputum samples.

In summary, we have demonstrated that targeted DNA sequencing is a simple, rapid, and accurate method for detecting PZA resistance that is suitable for clinical trials, as well as for routine testing of MDR-TB cases.

## ACKNOWLEDGMENTS

Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under awards UM1AI069521 and 7UM1AI068636-07. The content is solely our responsibility and does not necessarily represent the official views of the National Institutes of Health.

## REFERENCES

1. World Health Organization. 2008. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. World Health Organization, Geneva, Switzerland. [http://whqlibdoc.who.int/hq/2008/WHO\\_HTM\\_TB\\_2008.392\\_eng.pdf](http://whqlibdoc.who.int/hq/2008/WHO_HTM_TB_2008.392_eng.pdf).
2. Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F. 2010. Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of *Mycobacterium tuberculosis* to pyrazinamide. *J. Clin. Microbiol.* 48:300–301. <http://dx.doi.org/10.1128/JCM.01775-09>.
3. Scorpio A, Zhang Y. 1996. Mutations in *pncA*, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. *Nat. Med.* 2:662–667. <http://dx.doi.org/10.1038/nm0696-662>.
4. Hirano K, Takahashi M, Kazumi Y, Fukasawa Y, Abe C. 1997. Mutation in *pncA* is a major mechanism of pyrazinamide resistance in *Mycobacterium tuberculosis*. *Tuber. Lung Dis.* 78:117–122.
5. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. 2009. Tuberculosis drug resistance mutation database. *PLoS Med.* 6(2):e2. <http://dx.doi.org/10.1371/journal.pmed.1000002>.
6. Cui Z, Wang J, Lu J, Huang X, Zheng R, Hu Z. 2013. Evaluation of methods for testing the susceptibility of clinical *Mycobacterium tuberculosis* isolates to pyrazinamide. *J. Clin. Microbiol.* 51:1374–1380. <http://dx.doi.org/10.1128/JCM.03197-12>.
7. Huang TS, Lee SS, Tu HZ, Huang WK, Chen YS, Huang CK, Wann SR, Lin HH, Liu YC. 2003. Correlation between pyrazinamide activity and *pncA* mutations in *Mycobacterium tuberculosis* isolates in Taiwan. *Antimicrob. Agents Chemother.* 47:3672–3673. <http://dx.doi.org/10.1128/AAC.47.11.3672-3673.2003>.
8. Mphahlele M, Syre H, Valvatne H, Stavrum R, Mannsaker T, Muthivhi T, Weyer K, Fourie PB, Grewal HM. 2008. Pyrazinamide resistance among South African multidrug-resistant *Mycobacterium tuberculosis* isolates. *J. Clin. Microbiol.* 46:3459–3464. <http://dx.doi.org/10.1128/JCM.00973-08>.
9. Louw GE, Warren RM, Donald PR, Murray MB, Bosman M, van Helden PD, Young DB, Victor TC. 2006. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. *Int. J. Tuberc. Lung Dis.* 10:802–807.
10. Jnawali HN, Hwang SC, Park YK, Kim H, Lee YS, Chung GT, Choe KH, Ryoo S. 2013. Characterization of mutations in multi- and extensive drug resistance among strains of *Mycobacterium tuberculosis* clinical isolates in Republic of Korea. *Diagn. Microbiol. Infect. Dis.* 76:187–196. <http://dx.doi.org/10.1016/j.diagmicrobio.2013.02.035>.
11. Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE, III, Wang H, Zhang W, Zhang Y. 2011. Pyrazinamide inhibits trans-translation in *Mycobacterium tuberculosis*. *Science* 333:1630–1632. <http://dx.doi.org/10.1126/science.1208813>.
12. Simons SO, Mulder A, van IJ, Boeree MJ, Van SD. 2013. Role of *rpsA* gene sequencing in diagnosis of pyrazinamide resistance. *J. Clin. Microbiol.* 51:382. <http://dx.doi.org/10.1128/JCM.02739-12>.
13. Zhang Y, Mitchison D. 2003. The curious characteristics of pyrazinamide: a review. *Int. J. Tuberc. Lung Dis.* 7:6–21.